Eli Lilly Expands Camurus Collaboration
Analysis based on 10 articles · First reported Jun 01, 2026 · Last updated Jun 01, 2026
The expansion of the collaboration between Eli Lilly and Company and Camurus is expected to have a positive impact on both companies. Camurus' stock is likely to see an increase due to the upfront payment, potential milestone payments, and royalties, validating its Fluid Crystal technology. Eli Lilly and Company's stock may also benefit from the potential for new long-acting cardiometabolic drugs, expanding its product pipeline and market reach.
Eli Lilly and Company has expanded its collaboration with Camurus by exercising an option to include amylin receptor agonists in their existing license agreement. This decision grants Eli Lilly and Company exclusive global rights to Camurus' proprietary Fluid Crystal technology for developing and commercializing long-acting cardiometabolic drug candidates in an additional compound class. The agreement now covers up to four of Eli Lilly and Company's drug compounds across three classes: dual GLP-1 and GIP receptor agonists, triple GLP-1, GIP and glucagon receptor agonists, and amylin receptor agonists. As a result of this option exercise, Camurus will receive an initial payment of $5 million and is eligible for up to $290 million in upfront development and regulatory milestone payments, $580 million in sales-based milestone payments, and tiered mid-single-digit royalties on product sales. Fredrik Tiberg, President and CEO of Camurus, expressed satisfaction with the collaboration's progress and the validation of their Fluid Crystal technology, which is designed to deliver therapeutic drug levels over extended periods with a single injection and has commercial and regulatory approvals in Europe, the United States, and Australia.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard